Literature DB >> 16901518

Protection against MDMA-induced dopaminergic neurotoxicity in mice by methyllycaconitine: involvement of nicotinic receptors.

C Chipana1, J Camarasa, D Pubill, E Escubedo.   

Abstract

Methylenedioxymethamphetamine (MDMA) is a relatively selective dopaminergic neurotoxin in mice. Previous studies demonstrated the participation of alpha-7 nicotinic receptors (nAChR) in the neurotoxic effect of methamphetamine. The aim of this paper was to study the role of this receptor type in the acute effects and neurotoxicity of MDMA in mice. In vivo, methyllycaconitine (MLA), a specific alpha-7 nAChR antagonist, significantly prevented MDMA-induced neurotoxicity at dopaminergic but not at serotonergic level, without affecting MDMA-induced hyperthermia. Glial activation was also fully prevented by MLA. In vitro, MDMA induced intrasynaptosomal reactive oxygen species (ROS) generation, which was calcium-, nitric-oxide synthase-, and protein kinase C-dependent. Also, the increase in ROS was prevented by MLA and alpha-bungarotoxin. Experiments with reserpine point to endogenous dopamine (DA) as the main source of MDMA-induced ROS. MLA also brought the MDMA-induced inhibition of [3H]DA uptake down, from 73% to 11%. We demonstrate that a coordinated activation of alpha-7 nAChR, blockade of DA transporter function and displacement of DA from intracellular stores induced by MDMA produces a neurotoxic effect that can be prevented by MLA, suggesting that alpha-7 nAChR have a key role in the MDMA neurotoxicity in mice; however, the involvement of nicotinic receptors containing the beta2 subunit cannot be conclusively ruled out.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16901518     DOI: 10.1016/j.neuropharm.2006.05.032

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  7 in total

1.  MDMA enhances hippocampal-dependent learning and memory under restrictive conditions, and modifies hippocampal spine density.

Authors:  Sònia Abad; Alberto Fole; Nuria del Olmo; David Pubill; Mercè Pallàs; Fèlix Junyent; Jorge Camarasa; Antonio Camins; Elena Escubedo
Journal:  Psychopharmacology (Berl)       Date:  2013-10-26       Impact factor: 4.530

2.  Adaptive Plasticity in the Hippocampus of Young Mice Intermittently Exposed to MDMA Could Be the Origin of Memory Deficits.

Authors:  S Abad; J Camarasa; D Pubill; A Camins; E Escubedo
Journal:  Mol Neurobiol       Date:  2015-12-21       Impact factor: 5.590

3.  Pro-oxidant effects of Ecstasy and its metabolites in mouse brain synaptosomes.

Authors:  Daniel José Barbosa; João Paulo Capela; Jorge Ma Oliveira; Renata Silva; Luísa Maria Ferreira; Filipa Siopa; Paula Sério Branco; Eduarda Fernandes; José Alberto Duarte; Maria de Lourdes Bastos; Félix Carvalho
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

4.  Decreased withdrawal symptoms but normal tolerance to nicotine in mice null for the alpha7 nicotinic acetylcholine receptor subunit.

Authors:  Ramiro Salas; Adam Main; David Gangitano; Mariella De Biasi
Journal:  Neuropharmacology       Date:  2007-09-02       Impact factor: 5.250

5.  Suppression of complete Freund's adjuvant-induced adjuvant arthritis by cobratoxin.

Authors:  Yan-Li Liu; Hai-Ming Lin; Rong Zou; Jun-Chao Wu; Rong Han; Laurence N Raymond; Paul F Reid; Zheng-Hong Qin
Journal:  Acta Pharmacol Sin       Date:  2009-01-26       Impact factor: 6.150

6.  Repeated doses of methylone, a new drug of abuse, induce changes in serotonin and dopamine systems in the mouse.

Authors:  Raúl López-Arnau; José Martínez-Clemente; Sonia Abad; David Pubill; Jorge Camarasa; Elena Escubedo
Journal:  Psychopharmacology (Berl)       Date:  2014-04-05       Impact factor: 4.530

7.  A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse.

Authors:  W E Fantegrossi; J R Ciullo; K T Wakabayashi; R De La Garza; J R Traynor; J H Woods
Journal:  Neuroscience       Date:  2007-11-17       Impact factor: 3.590

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.